Covington & Burling advised Selecta Biosciences, Inc. on the transaction, and Foley Hoag advised Cartesian Therapeutics. Selecta Biosciences (Nasdaq:SELB) (“Selecta”) announced its merger with Cartesian Therapeutics and concurrent...
Selecta Biosciences’ Merger with Cartesian Therapeutics
Roivant Sciences’ $150 Million Equity Offering
Davis Polk advised Roivant Sciences Ltd. in the deal, while Covington represented the underwriter, Cantor Fitzgerald. Roivant Sciences Ltd. announced its debut SEC-registered offering of 30,000,000...
Marinus Pharmaceuticals’ $60 Million Public Offering
Covington represented the underwriters on the deal. Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,...
Immatics’ $110 Million Shares Offering
Davis Polk advised Immatics on the offering while Covington represented underwriters. Immatics N.V. executed its $110 million SEC-registered offering of ordinary shares. The ordinary shares are...
NewAmsterdam Pharma’s DeSPAC Merger with Frazier Lifesciences
Covington and NautaDutilh advised NewAmsterdam Pharma on the deal, while Latham & Watkins advised Lincoln International. Houthoff assisted Frazier Lifesciences Acquisition Corp. NewAmsterdam Pharma Holding B.V.,...